MA30651B1 - Derive heterocyclique fusionne et son procede d'utilisation. - Google Patents

Derive heterocyclique fusionne et son procede d'utilisation.

Info

Publication number
MA30651B1
MA30651B1 MA31647A MA31647A MA30651B1 MA 30651 B1 MA30651 B1 MA 30651B1 MA 31647 A MA31647 A MA 31647A MA 31647 A MA31647 A MA 31647A MA 30651 B1 MA30651 B1 MA 30651B1
Authority
MA
Morocco
Prior art keywords
relates
compound
heterocyclic derivative
fusioned
formula
Prior art date
Application number
MA31647A
Other languages
English (en)
Inventor
Nozomu Sakai
Shinichi Imamura
Naoki Miyamoto
Takaharu Hirayama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30651B1 publication Critical patent/MA30651B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un dérivé hétérocyclique fusionné présentant une puissante activité d'inhibition de kinase et son procédé d'utilisation. L'invention concerne un composé de formule (I). Dans cette formule, chaque symbole est tel qu'il est défini dans la description, à l'exception d'un composé particulier. L'invention concerne un sel du dérivé susmentionné et un agent pharmaceutique contenant ce composé ou un promédicament de celui-ci qui est un inhibiteur de kinase (VEGFR, VEGFR2, PDGFR, Raf), un inhibiteur d'angiogenèse, un agent de prophylaxie ou de traitement du cancer, un inhibiteur de croissance ou un suppresseur de métastases cancéreuses.
MA31647A 2006-08-04 2009-02-17 Derive heterocyclique fusionne et son procede d'utilisation. MA30651B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006331230 2006-12-07
JP2007144072 2007-05-30

Publications (1)

Publication Number Publication Date
MA30651B1 true MA30651B1 (fr) 2009-08-03

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31647A MA30651B1 (fr) 2006-08-04 2009-02-17 Derive heterocyclique fusionne et son procede d'utilisation.

Country Status (18)

Country Link
US (4) US8044049B2 (fr)
EP (1) EP2049541B1 (fr)
JP (1) JP5238697B2 (fr)
KR (1) KR20090047509A (fr)
AR (1) AR062207A1 (fr)
AU (1) AU2007279595A1 (fr)
BR (1) BRPI0714665A2 (fr)
CA (1) CA2659971A1 (fr)
CL (1) CL2007002261A1 (fr)
CO (1) CO6150183A2 (fr)
CR (1) CR10607A (fr)
IL (1) IL196799A0 (fr)
MA (1) MA30651B1 (fr)
MX (1) MX2009001349A (fr)
NO (1) NO20090986L (fr)
PE (1) PE20080538A1 (fr)
TW (1) TW200817409A (fr)
WO (1) WO2008016192A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
EP2181987B9 (fr) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles et leur utilisation dans la prévention ou le traitement du cancer
WO2009100375A1 (fr) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Imidazopyridazines substituées utiles en tant qu’inhibiteurs de kinase
UY31676A1 (es) 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
EP2277881A4 (fr) 2008-04-18 2011-09-07 Shionogi & Co Composé hétérocyclique présentant une activité inhibitrice sur p13k
WO2009136663A1 (fr) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Dérivés hétérocycliques fusionnés et leur utilisation
WO2010007099A1 (fr) * 2008-07-15 2010-01-21 Cellzome Limited Dérivés de 2-aminoimidazo[1,2-b]pyridazine en tant qu’inhibiteurs de pi3k
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP2012504591A (ja) 2008-10-02 2012-02-23 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
MX2011006219A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
US8637678B2 (en) 2008-12-24 2014-01-28 Syngenta Limited Methods for the preparation of aryl amides
MX2011008452A (es) 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2563792B1 (fr) 2010-04-28 2014-08-27 Bristol-Myers Squibb Company Composés d'imidazopyridazinyle et leurs utilisations pour le cancer
WO2012135781A1 (fr) * 2011-04-01 2012-10-04 Genentech, Inc. Combinaisons de composés inhibiteurs d'akt et d'agents chimiothérapeutiques, et procédés d'utilisation
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP2992112B1 (fr) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutations du gène pdgfrb et du gène notch3 responsables de la myofibromatose infantile autosomique dominante
HK1223307A1 (zh) * 2013-05-30 2017-07-28 Kala Pharmaceuticals, Inc. 新型化合物和其用途
EP3077393A1 (fr) * 2013-12-06 2016-10-12 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
UA119759C2 (uk) 2013-12-13 2019-08-12 Єврокем Агро Гмбх Суміш добрив, яка містить інгібітор нітрифікації
US10253045B2 (en) 2014-11-26 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
US20180028667A1 (en) * 2014-12-10 2018-02-01 Senju Pharmaceutical Co., Ltd. Aqueous liquid agent
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
EP3458456B1 (fr) 2016-05-18 2020-11-25 Loxo Oncology Inc. Préparation de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US20190152992A1 (en) 2016-06-29 2019-05-23 Orion Corporation Benzodioxane derivatives and their pharmaceutical use
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110177581B (zh) * 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
WO2020245208A1 (fr) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de cd9 en tant que biomarqueur et en tant que biocible dans la glomérulonéphrite ou la glomérulosclérose
JP7344971B2 (ja) 2019-09-12 2023-09-14 日本農薬株式会社 置換シクロプロパンオキサジアゾール基を有するイミダゾピリダジン化合物又はその塩類を有効成分とする農園芸用殺虫剤又は動物用の外部若しくは内部寄生虫防除剤並びに該使用方法
WO2021075477A1 (fr) * 2019-10-16 2021-04-22 国立大学法人京都大学 Inhibiteur de la dégénérescence des motoneurones
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN116456818B (zh) 2020-09-30 2025-12-05 住友化学株式会社 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物
WO2022192732A1 (fr) * 2021-03-12 2022-09-15 Gt Molecular, Llc Dosages génotypiques multiplexés réalisés avec une sonde unique utilisant un ajustement de l'amplitude de la fluorescence
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024088379A1 (fr) * 2022-10-27 2024-05-02 香港科技大学 Procédé de traitement ou de prévention d'une tumeur
WO2025086243A1 (fr) * 2023-10-27 2025-05-01 深圳湾实验室坪山生物医药研发转化中心 Inhibiteur de la tyrosine kinase du récepteur des leucocytes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001478A1 (fr) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES AVEC SUBSTITUANTS ARYLOXY ET ARALKYLTHIO
WO1989001333A1 (fr) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
ATE356117T1 (de) 1999-01-22 2007-03-15 Kirin Brewery Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
BRPI0418328A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd controle de parasitas em animais pelo uso de derivados de imidazo [1,2-b]piridazina
JP4935357B2 (ja) * 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
WO2006070943A1 (fr) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited Derive condense d'imidazole et applications de ce dernier
EP1910369A1 (fr) 2005-07-29 2008-04-16 Astellas Pharma Inc. Hétérocycles fusionnés en tant qu inhibiteurs de lck
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (fr) 2006-08-04 2010-12-22 Takeda Pharmaceutical Composé hétérocyclique à cycles fusionnés

Also Published As

Publication number Publication date
BRPI0714665A2 (pt) 2012-03-13
TW200817409A (en) 2008-04-16
US8034812B2 (en) 2011-10-11
WO2008016192A3 (fr) 2008-05-08
US8044049B2 (en) 2011-10-25
CA2659971A1 (fr) 2008-02-07
US20100273788A1 (en) 2010-10-28
IL196799A0 (en) 2009-11-18
MX2009001349A (es) 2009-04-17
AU2007279595A1 (en) 2008-02-07
KR20090047509A (ko) 2009-05-12
NO20090986L (no) 2009-05-04
JP2009545583A (ja) 2009-12-24
PE20080538A1 (es) 2008-06-18
US20090306374A1 (en) 2009-12-10
EP2049541B1 (fr) 2015-09-23
WO2008016192A2 (fr) 2008-02-07
US8273741B2 (en) 2012-09-25
AU2007279595A2 (en) 2009-03-19
CL2007002261A1 (es) 2008-05-02
CO6150183A2 (es) 2010-04-20
EP2049541A2 (fr) 2009-04-22
AR062207A1 (es) 2008-10-22
JP5238697B2 (ja) 2013-07-17
US20100168424A1 (en) 2010-07-01
CR10607A (es) 2009-03-12
US20090137595A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
MA30651B1 (fr) Derive heterocyclique fusionne et son procede d'utilisation.
Carta et al. Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII
EP3119753B1 (fr) 2-(2,4-difluorophényl)-1,1-difluoro-1-(pyridin-2-yl 5-substitué)-3-(1h-tétrazol-1-yl)propan-2-ols et procédés pour les préparer
Romagnoli et al. Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2, 4-dione
Grandane et al. Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII
MA38454A1 (fr) Inhibiteurs de protéines kinases
Grandane et al. 6-Triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrases IX and XII
de Moraes Gomes et al. New 1, 3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi
KR101716068B1 (ko) 신규한 퀴놀린 유도체 및 이의 적용
DE602004023838D1 (de) Hemmer der akt aktivität
MA32911B1 (fr) Derives de benzothiazole convenant comme agents agents anticancereux
US4873248A (en) Pyridinylpyrimidines having fungicidal activity
CN111683944A (zh) 杀真菌的噁二唑类
JP2017506237A (ja) アルツハイマー病治療用のｂａｃｅ１阻害剤としての２−アミノ−３，５，５−トリフルオロ−３，４，５，６−テトラヒドロピリジン
TR201816427T4 (tr) Bace1 inhibitörleri olarak 2-amino-6-(diflorometil)-5,5-difloro-6-fenil-3,4,5,6-tetrahidropiridinler.
JP2018533635A (ja) ４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１ｈ−１，２，４−トリアゾ−ル−１−イル）プロピル）ピリジン−３−イル）オキシ）ベンゾニトリル及び製造方法
EA018931B1 (ru) ДИЗАМЕЩЕННЫЕ ФТАЛАЗИНЫ-АНТАГОНИСТЫ СИГНАЛЬНОГО ПУТИ Hedgehog
KR100583667B1 (ko) 아리피프라졸의 제조방법
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
Mansour et al. Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma
A. Al-Qawasmeh et al. Design, synthesis and qualitative structure activity relationship evaluations of quinoline-based bisarylimidazoles as antibacterial motifs
Reddy et al. Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase
Kambappa et al. Synthesis, anti-angiogenic and DNA cleavage studies of novel N-(4-methyl-3-((4-(pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) piperidine-4-carboxamide derivatives
MA64128B1 (fr) Inhibiteurs de tead
Shi et al. Discovery of a novel dihydroisoquinolinone derivative as a potent CDK9 inhibitor capable of overcoming L156F mutant for the treatment of hematologic malignancies